PDE4B and chronic obstructive pulmonary disease: Thus, it is reasonable to believe that roflumilast may have anti-neuroinflammatory activity primarily by inhibiting PDE4B in BV-2 cells and mice, unlike the anti-inflammatory effect of PDE4A inhibition in COPD.